Now Accepting Nominations
2025 Harrington Prize for Innovation in Medicine
September 11, 2024
OXFORD, UK and CLEVELAND, Ohio, US, 11th September 2024 – The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the University of Oxford, UK and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, aimed at driving cutting-edge rare disease breakthroughs, announces the...
Continue Reading
March 13, 2024
The rapidly evolving SARS-CoV-2 virus threatens the progress made in curbing the COVID-19 pandemic. A promising novel drug candidate, designed at the atomic level, could help doctors halt the rise of lethal new drug resistant variants. Continue Reading
February 08, 2024
Dr. Paul Tesar of Case Western Reserve University and Dr. Donald F. Weaver of University Health Network selected for their work targeting novel pathways in Alzheimer’s Continue Reading
February 06, 2024
New Scholar Award Accelerates Novel Therapies for Rare Diseases Continue Reading
January 16, 2024
The Jenner Institute is conducting a new study, using BCG, the current licensed vaccine against tuberculosis. Continue Reading
January 03, 2024
Co-founder and president of Harrington Discovery Institute at University Hospitals receives highest professional distinction awarded solely to inventors Continue Reading
December 21, 2023
The study showed that all doses of ALX-001 were well tolerated, up to and including levels high enough to achieve full brain target engagement, supporting the company’s plans to continue clinical development for the treatment of Alzheimer’s disease. Continue Reading
December 13, 2023
The Harrington Family has been recognized in Cleveland Magazine's 2023 Faces of Cleveland as "The Faces of Life-Saving New Medicines" Continue Reading
December 08, 2023
Similar technology is gaining regulatory approval to treat sickle cell disease and drawing research attention to treat a wide range of health concerns Continue Reading
December 05, 2023
New cause of diabetes discovered, offering potential target for new classes of drugs to treat the disease Continue Reading
November 30, 2023
Sol-Gel Technologies, a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, begun Phase 3 testing of SGT-610 for Gorlin syndrome with the first patient screened. Continue Reading